On September 23, 2026, Oppenheimer initiated coverage of Pacira BioSciences (NASDAQGS:PCRX) with an “Outperform” recommendation. This marks a significant endorsement for the company focused on developing non-opioid pain management solutions, including its key product, EXPAREL, designed for post-surgical pain relief.
As of September 23, the stock closed at $24.63, down 1.12% from the previous week. The current analyst consensus target mean for the stock is $29.43, reflecting a potential increase of 19.51%. Recent data shows 13 total recommendations with 69.2% categorized as positive.
In its latest earnings report on August 4, 2026, Pacira reported an EPS of 0.73, surpassing estimates, with revenue of approximately $192.4 million, slightly below expectations.
5 Stocks Our Experts Predict Could Double In the Next Year
By submitting your email, you'll also get a free pivot & flow membership. A free daily market overview. You can unsubscribe at any time.
